NCT06378684View on ClinicalTrials.gov

To Evaluate the Safety and Pharmacokinetic Interactions in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

September 10, 2023

Primary Completion Date

December 23, 2023

Study Completion Date

January 13, 2024

Conditions

Healthy

Interventions

DRUG

Group 1: JW0104(Period 1), C2207(Period 2), JW0104 + C2207(Period 3)

Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration

DRUG

Group 2: JW0104 + C2207(Period 1), JW0104(Period 2), C2207(Period 3)

Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration

DRUG

Group 3: C2207(Period 1), JW0104 + C2207(Period 2), JW0104(Period 3)

Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration

DRUG

Group 4: JW0104(Period 1), JW0104 + C2207(Period 2), C2207(Period 3)

Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration

DRUG

Group 5: JW0104 + C2207(Period 1), C2207(Period 2), JW0104(Period 3)

Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration

DRUG

Group 6: C2207(Period 1), JW0104(Period 2), JW0104 + C2207(Period 3)

Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration

Trial Locations (1)

Unknown

Clinical Trial Center, Severance Hospital, Seoul

Sponsors

Lead Sponsor

JW Pharmaceutical

All Listed Sponsors

lead

JW Pharmaceutical

INDUSTRY

NCT06378684 - To Evaluate the Safety and Pharmacokinetic Interactions in Healthy Volunteers | Biotech Hunter | Biotech Hunter